高级检索
当前位置: 首页 > 详情页

Left bundle branch pacing in heart failure patients with left bundle branch block: A systematic review and meta-analysis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Cardiology, Affiliated Hospitalof Hebei University, YuHua street, Baoding,Hebei 071000, China
出处:
ISSN:

关键词: biventricular pacing cardiac resynchronization therapy heart failure left bundle branch pacing left bundle branch block

摘要:
Background The clinical benefit of cardiac resynchronization therapy (CRT) in heart failure patients with left bundle branch block (LBBB) has been demonstrated. However, a nonresponse rate of CRT nearly 1/3. Recent studies have reported left bundle branch pacing (LBBP) has achieved remarkable effect in CRT. This study aim to explore the efficacy and safety of LBBP in heart failure patients with LBBB. Methods We searched PubMed, Cochrane Library, Web of science, and CNKI databases for studies about LBBP in heart failure patients with LBBB. QRS duration (QRSd), New York Heart Association (NYHA) classification, B-type natriuretic peptide (BNP) concentration, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), pacing threshold and other related data were extracted and summarized. Results A total of 6 studies were included, and the success rate of LBBP was 93.2%. Compared with baseline, LBBP could shorten QRSd (MD = 61.23, 95% CI: 58.21-64.25, p < .01). Echocardiographic parameters including LVEF and LVEDD significantly improved (both with p < .01). Clinical outcomes including NYHA classification and BNP dramatically reduced (both with p < .01). Compared with biventricular pacing (BVP), LBBP could further improve QRSd, LVEF, LVEDD, and NYHA classification (all with p < .01). However, the pacing threshold at follow-up was 0.06 V higher than that at baseline (p < .01), and the incidence of complications was 2.4%. Conclusions LBBP is effective and safe in heart failure patients with LBBB, whether it is better than BVP needs to be verified by randomized controlled trials.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 工程:生物医学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 工程:生物医学
JCR分区:
出版当年[2022]版:
Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Q4 ENGINEERING, BIOMEDICAL
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Q3 ENGINEERING, BIOMEDICAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Cardiology, Affiliated Hospitalof Hebei University, YuHua street, Baoding,Hebei 071000, China
通讯作者:
通讯机构: [1]Department of Cardiology, Affiliated Hospitalof Hebei University, YuHua street, Baoding,Hebei 071000, China [*1]Department of Cardiology Affiliated Hospital of Hebei University, YuHuaStreet, Baoding, Hebei, 071000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15100 今日访问量:0 总访问量:960 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号